
Biopharmaceutical company in Bridgewater, NJ, transforming lives of patients with serious diseases.
Insmed Incorporated, founded in Bridgewater, New Jersey, is a biopharmaceutical company dedicated to transforming the lives of patients with serious and rare diseases. Their core mission is to develop and commercialize innovative therapies that address unmet medical needs. Insmed offers ARIKAYCE for treating Mycobacterium avium complex lung disease and is developing Brensocatib for bronchiectasis, cystic fibrosis, and other neutrophil-mediated diseases. The company focuses on providing life-changing solutions for patients globally.
Notable figures associated with Insmed include its leadership team and key investors who support its mission to advance medical science. The company has achieved significant milestones, including the successful commercialization of ARIKAYCE and ongoing clinical trials for Brensocatib. Insmed's impact is profound, as it continues to make a difference in the lives of patients worldwide through its commitment to daring science and a collaborative culture.

Pulmatrix
pulmatrix.com

MediciNova
medicinova.com
MannKind
mannkindcorp.com
Bristol Myers Squibb
bms.com

Amphastar Pharmaceuticals
amphastar.com
Vertex Pharmaceuticals
vrtx.com

Intellimedix

Inception Sciences

Theravance Biopharma
theravance.com
Assertio Holdings

Medinox
medinox.com

Innovation Pharmaceuticals
ipharminc.com

Complexa

HI-Bio
hibio.com

Bridge Medicines
Companies similar to Insmed include Pulmatrix, MediciNova, MannKind and Bristol Myers Squibb.
Insmed was founded in 1999.
Insmed's headquarters is located in Bridgewater Township, NJ, US.
Insmed's most recent funding round was for $500k (USD) in May 2023.
As of May 8, 2023, Insmed has raised a total of $3B (USD).
Insmed has 736 employees as of Feb 6, 2024.